Search

Displaying results 611 - 620 of 10000 in total
  1. Drug

    Avobenzone

    go.drugbank.com/drugs/DB09495
    ApprovedInvestigational

    It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … Avobenzone is very sensitive to light, to increase its stability and duration of action, photostablizers are added in the sunscreen product. Avobenzone has an absorption maximum of 357 nm.

    Mixtures: Gold Bond Ultimate 5-in-1 Face, Bullet LineCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States.

    Mixtures: EXFORGE® 10/320 COMPRIMIDOS CON CUBIERTA PELICULAR, EXFORGE® 5/80 MG COMPRIMIDOS CON CUBIERTA PELICULARCategories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Meloxicam

    go.drugbank.com/drugs/DB00814
    ApprovedInvestigationalVet approved

    Meloxicam is available in oral, transdermal, and intravenous formulations.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticProducts: MELOXICAM EG
  4. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.

    Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamide
  5. Drug

    Etodolac

    go.drugbank.com/drugs/DB00749
    ApprovedInvestigationalVet approved

    Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.

    Mixtures: NuDroxiPAK E-400Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  6. Drug

    Loratadine

    go.drugbank.com/drugs/DB00455
    ApprovedInvestigational

    [A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.

    Mixtures: DESENFRIOL-ON GRAGEAS REPETABS, LARITOL EXCategories: Histamine H1 Antagonists, Non-Sedating
  7. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.

    Categories: Drugs Used in Erectile Dysfunction, Drugs Used in Benign Prostatic HypertrophyProducts: TADALAFIL EG, TADALAFIL EG STADA
  8. Drug

    Pantoprazole

    go.drugbank.com/drugs/DB00213
    ApprovedInvestigational

    [FDA Label] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. … increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.

    Products: PANTOPRAZOLO EG, PANTO 40 MG IV ENJ. LIYOFILIZE TOZ ICEREN FLAKON
  9. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … [L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors

    Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine
  10. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle.

    Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide